OTCMKTS:LTUS

Lotus Pharmaceuticals Competitors

$0.05
0.00 (0.00 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.05
Now: $0.05
$0.05
50-Day Range
$0.04
MA: $0.11
$0.20
52-Week Range
$0.01
Now: $0.05
$0.22
VolumeN/A
Average Volume167,911 shs
Market Capitalization$146.93 million
P/E RatioN/A
Dividend YieldN/A
Beta1.29

Competitors

Lotus Pharmaceuticals (OTCMKTS:LTUS) Vs. OGI, EGRX, RLMD, MIRM, SIGA, and CRNX

Should you be buying LTUS stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Lotus Pharmaceuticals, including OrganiGram (OGI), Eagle Pharmaceuticals (EGRX), Relmada Therapeutics (RLMD), Mirum Pharmaceuticals (MIRM), SIGA Technologies (SIGA), and Crinetics Pharmaceuticals (CRNX).

Lotus Pharmaceuticals (OTCMKTS:LTUS) and OrganiGram (NASDAQ:OGI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, earnings, dividends and profitability.

Profitability

This table compares Lotus Pharmaceuticals and OrganiGram's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lotus PharmaceuticalsN/AN/AN/A
OrganiGram-207.26%-10.00%-7.14%

Risk and Volatility

Lotus Pharmaceuticals has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500. Comparatively, OrganiGram has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Lotus Pharmaceuticals and OrganiGram, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lotus Pharmaceuticals0000N/A
OrganiGram16402.27

OrganiGram has a consensus price target of $4.4113, indicating a potential upside of 75.05%. Given OrganiGram's higher possible upside, analysts plainly believe OrganiGram is more favorable than Lotus Pharmaceuticals.

Valuation & Earnings

This table compares Lotus Pharmaceuticals and OrganiGram's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lotus PharmaceuticalsN/AN/AN/AN/AN/A
OrganiGram$64.61 million9.06$-101,290,000.00($0.08)-31.50

Lotus Pharmaceuticals has higher earnings, but lower revenue than OrganiGram.

Institutional & Insider Ownership

10.8% of OrganiGram shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Eagle Pharmaceuticals (NASDAQ:EGRX) and Lotus Pharmaceuticals (OTCMKTS:LTUS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, valuation, earnings and profitability.

Profitability

This table compares Eagle Pharmaceuticals and Lotus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eagle Pharmaceuticals2.65%8.50%5.44%
Lotus PharmaceuticalsN/AN/AN/A

Institutional and Insider Ownership

95.1% of Eagle Pharmaceuticals shares are held by institutional investors. 21.1% of Eagle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Risk and Volatility

Eagle Pharmaceuticals has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, Lotus Pharmaceuticals has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Eagle Pharmaceuticals and Lotus Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eagle Pharmaceuticals01002.00
Lotus Pharmaceuticals0000N/A

Eagle Pharmaceuticals presently has a consensus price target of $46.00, indicating a potential upside of 3.91%. Given Eagle Pharmaceuticals' higher possible upside, analysts clearly believe Eagle Pharmaceuticals is more favorable than Lotus Pharmaceuticals.

Valuation and Earnings

This table compares Eagle Pharmaceuticals and Lotus Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eagle Pharmaceuticals$195.89 million2.99$14.31 million$1.3832.08
Lotus PharmaceuticalsN/AN/AN/AN/AN/A

Eagle Pharmaceuticals has higher revenue and earnings than Lotus Pharmaceuticals.

Summary

Eagle Pharmaceuticals beats Lotus Pharmaceuticals on 7 of the 8 factors compared between the two stocks.

Lotus Pharmaceuticals (OTCMKTS:LTUS) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, valuation, risk and dividends.

Institutional & Insider Ownership

64.3% of Relmada Therapeutics shares are held by institutional investors. 9.3% of Relmada Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Lotus Pharmaceuticals and Relmada Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lotus PharmaceuticalsN/AN/AN/A
Relmada TherapeuticsN/A-32.03%-31.41%

Risk and Volatility

Lotus Pharmaceuticals has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, Relmada Therapeutics has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500.

Valuation and Earnings

This table compares Lotus Pharmaceuticals and Relmada Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lotus PharmaceuticalsN/AN/AN/AN/AN/A
Relmada TherapeuticsN/AN/AN/A($2.16)-16.06

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Lotus Pharmaceuticals and Relmada Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lotus Pharmaceuticals0000N/A
Relmada Therapeutics01202.67

Relmada Therapeutics has a consensus target price of $63.3333, indicating a potential upside of 82.57%. Given Relmada Therapeutics' higher probable upside, analysts plainly believe Relmada Therapeutics is more favorable than Lotus Pharmaceuticals.

Summary

Relmada Therapeutics beats Lotus Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

Mirum Pharmaceuticals (NASDAQ:MIRM) and Lotus Pharmaceuticals (OTCMKTS:LTUS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Analyst Recommendations

This is a breakdown of current ratings for Mirum Pharmaceuticals and Lotus Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mirum Pharmaceuticals00613.14
Lotus Pharmaceuticals0000N/A

Mirum Pharmaceuticals presently has a consensus target price of $40.1667, indicating a potential upside of 117.82%. Given Mirum Pharmaceuticals' higher probable upside, equities analysts plainly believe Mirum Pharmaceuticals is more favorable than Lotus Pharmaceuticals.

Risk and Volatility

Mirum Pharmaceuticals has a beta of 2.44, suggesting that its stock price is 144% more volatile than the S&P 500. Comparatively, Lotus Pharmaceuticals has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500.

Profitability

This table compares Mirum Pharmaceuticals and Lotus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mirum PharmaceuticalsN/A-61.90%-54.46%
Lotus PharmaceuticalsN/AN/AN/A

Institutional & Insider Ownership

72.9% of Mirum Pharmaceuticals shares are owned by institutional investors. 45.5% of Mirum Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Mirum Pharmaceuticals and Lotus Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mirum PharmaceuticalsN/AN/A$-52,550,000.00($4.58)-4.03
Lotus PharmaceuticalsN/AN/AN/AN/AN/A

Summary

Mirum Pharmaceuticals beats Lotus Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

Lotus Pharmaceuticals (OTCMKTS:LTUS) and SIGA Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Lotus Pharmaceuticals and SIGA Technologies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lotus Pharmaceuticals0000N/A
SIGA Technologies0000N/A

Profitability

This table compares Lotus Pharmaceuticals and SIGA Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lotus PharmaceuticalsN/AN/AN/A
SIGA Technologies34.62%37.31%25.33%

Earnings and Valuation

This table compares Lotus Pharmaceuticals and SIGA Technologies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lotus PharmaceuticalsN/AN/AN/AN/AN/A
SIGA Technologies$26.74 million20.84$-7,240,000.00N/AN/A

Lotus Pharmaceuticals has higher earnings, but lower revenue than SIGA Technologies.

Risk and Volatility

Lotus Pharmaceuticals has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, SIGA Technologies has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500.

Institutional and Insider Ownership

29.3% of SIGA Technologies shares are held by institutional investors. 3.9% of SIGA Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

SIGA Technologies beats Lotus Pharmaceuticals on 6 of the 7 factors compared between the two stocks.

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Lotus Pharmaceuticals (OTCMKTS:LTUS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

Institutional and Insider Ownership

92.2% of Crinetics Pharmaceuticals shares are held by institutional investors. 7.1% of Crinetics Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Crinetics Pharmaceuticals has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Comparatively, Lotus Pharmaceuticals has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Crinetics Pharmaceuticals and Lotus Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Crinetics Pharmaceuticals01302.75
Lotus Pharmaceuticals0000N/A

Crinetics Pharmaceuticals currently has a consensus price target of $35.00, suggesting a potential upside of 109.21%. Given Crinetics Pharmaceuticals' higher probable upside, equities analysts clearly believe Crinetics Pharmaceuticals is more favorable than Lotus Pharmaceuticals.

Profitability

This table compares Crinetics Pharmaceuticals and Lotus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Crinetics PharmaceuticalsN/A-43.35%-39.73%
Lotus PharmaceuticalsN/AN/AN/A

Valuation & Earnings

This table compares Crinetics Pharmaceuticals and Lotus Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Crinetics Pharmaceuticals$1.19 million464.35$-50,420,000.00($2.09)-8.00
Lotus PharmaceuticalsN/AN/AN/AN/AN/A

Lotus Pharmaceuticals has lower revenue, but higher earnings than Crinetics Pharmaceuticals.

Summary

Crinetics Pharmaceuticals beats Lotus Pharmaceuticals on 5 of the 8 factors compared between the two stocks.


Lotus Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
OrganiGram logo
OGI
OrganiGram
1.6$2.52flat$585.32 million$64.61 million-3.71Earnings Announcement
Analyst Report
Decrease in Short Interest
Analyst Revision
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.2$44.27flat$585.12 million$195.89 million126.49News Coverage
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$34.69flat$580.95 millionN/A-16.06
Mirum Pharmaceuticals logo
MIRM
Mirum Pharmaceuticals
1.8$18.44flat$560.95 millionN/A-5.36
SIGA Technologies logo
SIGA
SIGA Technologies
0.3$7.26flat$557.19 million$26.74 million18.15
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.8$16.73flat$552.58 million$1.19 million-6.97
Basilea Pharmaceutica logo
BPMUF
Basilea Pharmaceutica
0.6$50.20flat$539.18 million$135.28 million-24.02Analyst Upgrade
IVERIC bio logo
ISEE
IVERIC bio
1.5$5.95flat$536.51 millionN/A-4.72
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$11.00flat$534.12 millionN/A-5.64Analyst Upgrade
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.8$11.28flat$532.95 millionN/A-8.74Increase in Short Interest
Urovant Sciences logo
UROV
Urovant Sciences
0.7$16.24flat$531.75 millionN/A-3.15
RAPT Therapeutics logo
RAPT
RAPT Therapeutics
1.6$20.87flat$518.95 millionN/A-8.22Unusual Options Activity
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$14.11flat$516.12 millionN/A-4.07
Inventiva logo
IVA
Inventiva
0.0$13.34flat$515.32 millionN/A0.00
Provention Bio logo
PRVB
Provention Bio
1.6$8.11flat$513.97 millionN/A-5.44Analyst Report
Increase in Short Interest
Neoleukin Therapeutics logo
NLTX
Neoleukin Therapeutics
1.4$11.96flat$506.22 million$25 million-18.40
Avadel Pharmaceuticals logo
AVDL
Avadel Pharmaceuticals
1.5$8.62flat$503.97 million$59.22 million43.10
Forte Biosciences logo
FBRX
Forte Biosciences
1.7$36.80flat$497.13 million$40,000.00-1.60Upcoming Earnings
XBiotech logo
XBIT
XBiotech
1.0$16.81flat$495.21 millionN/A1.16
89bio logo
ETNB
89bio
1.6$24.77flat$494.06 millionN/A-4.90
Amryt Pharma logo
AMYT
Amryt Pharma
1.4$13.75flat$493.31 million$58.12 million-15.99Decrease in Short Interest
CytomX Therapeutics logo
CTMX
CytomX Therapeutics
1.6$7.51flat$486.53 million$57.49 million-6.31Increase in Short Interest
AC Immune logo
ACIU
AC Immune
1.3$6.73flat$484.14 million$111.75 million-7.48
Evolus logo
EOLS
Evolus
1.5$10.97flat$479.75 million$34.92 million-5.40Analyst Report
TherapeuticsMD logo
TXMD
TherapeuticsMD
1.5$1.19flat$478.45 million$49.65 million-1.68Analyst Upgrade
Akouos logo
AKUS
Akouos
1.6$13.76flat$473.37 millionN/A0.00
Flexion Therapeutics logo
FLXN
Flexion Therapeutics
1.4$9.41flat$469.79 million$72.96 million-3.05Analyst Report
Analyst Revision
Geron logo
GERN
Geron
1.4$1.47flat$468.24 million$460,000.00-4.20Decrease in Short Interest
Verona Pharma logo
VRNA
Verona Pharma
1.7$8.00flat$463.48 millionN/A-2.43
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.00flat$461.18 million$109.33 million-2.21
Catalyst Pharmaceuticals logo
CPRX
Catalyst Pharmaceuticals
1.7$4.44flat$460.98 million$102.31 million6.63Increase in Short Interest
Verastem logo
VSTM
Verastem
1.3$2.68flat$460.07 million$17.46 million-1.90
Kala Pharmaceuticals logo
KALA
Kala Pharmaceuticals
1.7$7.47flat$459.79 million$6.07 million-3.57
Altimmune logo
ALT
Altimmune
1.9$12.27flat$455.83 million$5.80 million-6.17Increase in Short Interest
Molecular Templates logo
MTEM
Molecular Templates
2.0$8.12flat$455.14 million$22.27 million-3.98Analyst Report
Insider Buying
Analyst Revision
Akebia Therapeutics logo
AKBA
Akebia Therapeutics
1.8$2.96flat$454.37 million$335 million-1.00
Viking Therapeutics logo
VKTX
Viking Therapeutics
1.6$5.87flat$453.04 millionN/A-11.98News Coverage
Summit Therapeutics logo
SMMT
Summit Therapeutics
0.6$5.36flat$444.43 million$56.50 million0.00Analyst Downgrade
Inozyme Pharma logo
INZY
Inozyme Pharma
1.7$18.60flat$436.43 millionN/A0.00Gap Down
BCEL
Atreca
1.7$11.81flat$434.97 millionN/A-4.19
Selecta Biosciences logo
SELB
Selecta Biosciences
1.6$3.87flat$434.88 million$6.68 million-4.66
MedAvail logo
MDVL
MedAvail
1.9$13.45flat$429.59 million$1.03 million-3.30Increase in Short Interest
Applied Therapeutics logo
APLT
Applied Therapeutics
1.8$16.39flat$426.29 millionN/A-3.44
Foghorn Therapeutics logo
FHTX
Foghorn Therapeutics
1.5$11.50flat$423.40 millionN/A0.00Lockup Expiration
ANI Pharmaceuticals logo
ANIP
ANI Pharmaceuticals
1.9$34.18flat$422.64 million$206.55 million-17.18
XOMA logo
XOMA
XOMA
1.3$37.50flat$422.18 million$18.37 million-33.78Increase in Short Interest
Seelos Therapeutics logo
SEEL
Seelos Therapeutics
1.3$5.26flat$411.77 million$380,000.000.00Analyst Upgrade
News Coverage
Puma Biotechnology logo
PBYI
Puma Biotechnology
1.4$10.07flat$405.40 million$272.30 million-7.04
Nature's Sunshine Products logo
NATR
Nature's Sunshine Products
0.9$20.23flat$400.47 million$362.21 million24.37
Aeglea BioTherapeutics logo
AGLE
Aeglea BioTherapeutics
1.7$8.17flat$392.29 million$3.89 million-4.28Gap Down
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.